SPARTAN Trial Updates, With Jonathan Barratt, MD, PhD
Spartan trial updates, with jonathan barratt, md, phd. Jonathan barratt, phd, frcp. Sparsentan is a dual endothelin and angiotensin ii receptor blocker that slows kidney function decline and proteinuria in patients with iga nephropathy. Learn about the latest clinical trials,. Protect trial, which showed a 41% greater decline in proteinuria for patients treated with sparsentan versus those treated with an angiotensin ii receptor blocker (arb) alone
Barratt reflects on recent therapeutic developments in igan, the most recent being the full fda approval of sparsentan (filspari),.